Chemoprotection and enhancement of cancer chemotherapeutic efficacy of cyclophosphamide in mice bearing Ehrlich ascites carcinoma by diphenylmethyl selenocyanate.
OBJECTIVE
Chemoprotective effect of diphenylmethyl selenocyanate against cyclophosphamide (CP) induced cellular toxicity and antitumor efficacy was evaluated in mice bearing Ehrlich ascites carcinoma.


METHODS
Diphenylmethyl selenocyanate (3 mg/kg.b.w.) was administered orally and CP was given intraperitoneally (25 mg/kg.b.w). The effects were observed on the level of lipid peroxidation, antioxidant enzymes status, serum transaminase (ALT, AST) activity, hematological profile, transplantable murine tumor growth, apoptosis induction in tumor cells, and life span of tumor bearing hosts.


RESULTS
The selenium compound restored the levels of antioxidant enzymes system, decreased the level of lipid peroxidation and serum transaminase activity. Hematological profile reverted to near normal level after selenium compound treatment. Treatment with the selenium compound also resulted in significant tumor growth regression along with significant upregulation of apoptosis, increased in mean survival time and life span of tumor bearing host.


CONCLUSIONS
Results clearly indicate that diphenylmethyl selenocyanate has the potential to reduce the cellular toxicity of CP at the same time improving its antitumor efficacy.
Chakraborty
Pramita
P
Department of Cancer Chemoprevention, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India.
Sk
Ugir Hossain
UH
Bhattacharya
Sudin
S
D000410:Alanine Transaminase / Q000378:metabolism; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D001219:Aspartate Aminotransferases / Q000378:metabolism; D001772:Blood Cell Count; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000473:pathology; D002374:Catalase / Q000378:metabolism; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004357:Drug Synergism; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D005982:Glutathione Transferase / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D051379:Mice; D016566:Organoselenium Compounds / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000378:metabolism; D016019:Survival Analysis
D018906:Antineoplastic Agents, Alkylating; D000975:Antioxidants; D016566:Organoselenium Compounds; C495419:diphenylmethyl selenocyanate; D003520:Cyclophosphamide; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005982:Glutathione Transferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005978:Glutathione